2.1 Release Notes - Marazion

Information

Eva are pleased to announce the release of yet another module within the eVacc application. A new tab allows the display of further demographic based information and is just one more step along the journey continuing to build a clinical application at the forefront of innovation and design.

Patient Demographics

Within **eVacc** the first phase of the new module '**Demographics**' has been released.



This tab presents a **READ ONLY** view of the patient's demographic information which has been retrieved from the Personal Demographic Service (PDS) for the patient currently loaded.

The information presented within this module contains **Basic Key Information** including First Name, Surname, Date of Birth, NHS Number, potential **Sensitive Information**, currently registered **Address** details and methods of **Communication** including email addresses and telephone numbers.





The first phase of this module allows the user to **ONLY VIEW** the information and amendments are currently not supported. As **eVacc** continues to develop another uplift to this module will be released allowing information within this tab to be modified and held as local patient information alongside updating the PDS record which will then flow to all PDS enabled health care systems.

Patient Screening and Consent

[EF-2776] - Update Warning Message to Allow Booster Doses for `at-risk` 12-15 year olds

A Point of Care specification change by NHSD in response to JCVI guidance means that booster doses to children aged 12 to 15 years who are severely immunosuppressed and who have had a third primary dose can now be administered.

The eVacc solution now allows the user to select a **BOOSTER** dose for an **immunosuppressed, clinically extremely vulnerable, or household contact patient** 12 - 15 years of age, **or** a patient that has received a third dose of their primary course, without displaying this warning message.

Children 12-15 Scheduling & Dosing

There is an update to the 3rd and 4th columns relating to the number of days between primary and booster doses, and between booster doses.

Children aged 12-15 years of age are now permitted to have a Booster vaccination 91 days after completion of their Primary course.

Vaccine Name	Scheduling				Dose Amounts	
	Minimum interval between 1st and 2nd dose [1]	Minimum interval between 2nd and subsequent primary course doses where required [2]	Minimum interval between primary course and booster doses [3]	Minimum interval between booster doses [3]	Primary course	Booster dose
Comirnaty COVID-19 mRNA Vaccine 30micrograms/0.3ml dose concentrate for dispersion for injection multidose vials (Pfizer)	84 days	56 days	91 days	91 days	0.3ml	0.3ml
COVID-19 Vaccine AstraZeneca (ChAdOx1 S [recombinant]) 5x10,000,000,000 viral particles/0.5ml dose suspension for injection multidose vials [4]	84 days	56 days	91 days	91 days	0.5ml	0.5ml
Spikevax COVID-19 mRNA (nucleoside modified) Vaccine 0.1mg/0.5ml dose dispersion for injection multidose vials (Moderna) **[4]**	84 days	56 days	91 days	91 days	0.5ml	0.25ml

Note:
[1] For individuals in this cohort that are in a risk group (including those identified as severely immunosuppressed) the minimum interval is 56 days
[2] Only those individuals that are severely immunosuppressed in this cohort can be eligible for a 3rd primary dose
[3] ***Updated*** Based on current JCVI guidance, only adults (16+) and those aged 12+ in an at-risk group are eligible for booster doses, however, those that are severely immunosuppressed in this cohort who have received a 3rd primary dose will be eligible for a booster dose